Skip to content

Home - Media - Press releases - 2003    
13 February 2003
ASTRAZENECA SUBMITS INFORMATION AMENDMENT FOR CRESTOR® (ROSUVASTATIN CALCIUM) NDA TO FDA

AstraZeneca announced today the submission of an information amendment to its New Drug Application (NDA) for CRESTOR® (rosuvastatin calcium) Tablets in response to the US Food and Drug Administration (FDA) approvable letter of May 2002.

The additional data provide further support for the proposed use of CRESTOR® Tablets for the treatment of patients for the management of hypercholesterolaemia, mixed dyslipidaemia and isolated hypertriglyceridaemia.

Further enquires to:

Media Enquiries

Emily Denney
+44 (0)20 7304 5034

Steve Brown
+44 (0)20 7304 5033


Investor Relations

Mina Blair-Robinson
+44 (0)20 7304 5084

Jonathan Hunt
+44 (0)20 7304 5087
AstraZeneca websites
Search
 Terms of use  Privacy policy    © AstraZeneca PLC 2003 - 2008